|
Re: Saudi
|
3
|
Resverlogix Corp.
|
Jan 19, 2021 06:21PM
|
|
Re: Sachs conference with Bioasis
|
2
|
BIOASIS TECHNOLOGIES INC
|
Mar 24, 2022 02:56PM
|
|
Re: RVX on local Calgary CTV at 5 and 6pm on 11 March
|
3
|
Resverlogix Corp.
|
Mar 12, 2021 03:43PM
|
|
Re: RVX Announces Update Webcast and Conference Call
|
5
|
Resverlogix Corp.
|
Jan 19, 2021 06:28PM
|
|
Re: rumours have been flying around the last ...
|
2
|
Zenith Epigenetics
|
Mar 03, 2021 04:21PM
|
|
Re: RSU's awarded
|
1
|
Resverlogix Corp.
|
Sep 19, 2019 02:16PM
|
|
Re: Roll call,...
|
4
|
Resverlogix Corp.
|
Sep 30, 2019 06:51AM
|
|
Re: Revised target market, indications, market potential? ... and some numbers?
|
1
|
Resverlogix Corp.
|
Jun 15, 2020 12:39PM
|
|
Re: Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
|
3
|
Resverlogix Corp.
|
Apr 27, 2021 04:30PM
|
|
Re: Resverlogix spinout inks R&D deal with cancer institute
|
3
|
Resverlogix Corp.
|
Oct 05, 2020 11:46AM
|
|
Re: Resverlogix Reschedules Update Webcast and Conference Call: Now February 4th 10AM MT
|
7
|
Resverlogix Corp.
|
Jan 28, 2021 08:36AM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
8
|
Resverlogix Corp.
|
Jun 22, 2020 07:41AM
|
|
Re: Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research
|
3
|
Resverlogix Corp.
|
Mar 23, 2020 10:19AM
|
|
Re: Resverlogix Announces Publication on Apabetalone in Cardiovascular Therapeutics
|
5
|
Resverlogix Corp.
|
Aug 04, 2020 02:41PM
|
|
Re: Resverlogix Announces One-Year Extension of Debenture
|
2
|
Resverlogix Corp.
|
Apr 21, 2022 05:01PM
|
|
Re: Resverlogix Announces Annual and Special Meeting of Shareholders
|
6
|
Resverlogix Corp.
|
Aug 22, 2019 09:57PM
|
|
Re: Recent presentations
|
4
|
Resverlogix Corp.
|
Dec 13, 2021 08:15PM
|
|
Re: Prospects for resverlogix
|
5
|
Resverlogix Corp.
|
Jul 15, 2020 09:09AM
|
|
Re: Primary outcome HR= .82 (18% RRR) P=0.11
|
1
|
Resverlogix Corp.
|
Nov 16, 2019 12:07PM
|
|
Re: Pharmacological Modulation of BET Family in Sepsis
|
2
|
Resverlogix Corp.
|
Mar 11, 2021 06:45PM
|
